The biotechnology company has filed an amendment to include children and adolescents with relapsed/refractory acute myeloid leukemia in its ongoing Phase I clinical trial for its CAR-T therapy HG-CT-1.
The biotechnology company has issued a correction to the resolutions in its recent AGM notice, fixing a clerical error related to the authorities sought by the directors.
The biotechnology company has raised £451,250 to continue its Phase I clinical trials for a new cancer treatment, with the funds secured at a small 1.6% discount to the previous share price.
The biopharmaceutical company has announced details for its upcoming Annual General Meeting.
The biotechnology company has successfully treated a second patient as part of its ongoing Phase I clinical trial for its HG-CT-1 CAR-T therapy, a potential treatment for relapsed or refractory acute myeloid leukemia.
The clinical-stage biotechnology firm has progressed to Phase I trials for its lead product, but faces significant financial challenges with a rapidly diminishing cash position and ongoing losses.
The biotechnology company has submitted its annual report to the FDA on its investigational new drug application for a CAR-T therapy to treat acute myeloid leukemia.
The biotechnology company reports the successful treatment of the first patient with its HG-CT-1 CAR-T therapy, with no adverse effects observed.
The biotechnology company has recruited the second patient for its clinical trial of a proprietary CAR-T cell therapy for the treatment of relapsed or refractory acute myeloid leukemia.
The biotechnology company has converted its convertible loan notes into ordinary shares, simplifying its capital structure.